ArticleAntimicrobial agents and chemotherapy2020
Vancomycin Heteroresistance and Clinical Outcomes in Bloodstream Infections Caused by Coagulase-Negative Staphylococci.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Bacterial strategies for surviving antibiotics during urinary tract infection: could uropathogenic Escherichia coli be persisters?Nature reviews. Urology · 2026Review
- Evaluation of an adapted relative growth method by MALDI-TOF MS for rapid determination of the susceptibility ofMicrobiology spectrum · 2026Article
- Development and clinical application of a PCR-UV assay for detection of carbapenem resistant Acinetobacter baumannii in bloodstream infections.Microbial cell factories · 2025Article
- Flying under the radar: vancomycin heteroresistance inASM case reports · 2025Article
- Glycopeptide Heteroresistance Among Coagulase-Negative Staphylococci: A Systematic Review and Meta-analysis.Open forum infectious diseases · 2025Article
- Review
- Prevalence, misclassification, and clinical consequences of the heteroresistant phenotype in Escherichia coli bloodstream infections in patients in Uppsala, Sweden: a retrospective cohort study.The Lancet. Microbe · 2025Article
- Mechanisms ofInternational journal of molecular sciences · 2025Article
- The pathogenicity and virulence of the opportunistic pathogenVirulence · 2024Review
- Multidrug-ResistantMicroorganisms · 2024Article
- High prevalence of heteroresistance in Staphylococcus aureus is caused by a multitude of mutations in core genes.PLoS biology · 2024Article
- Development and clinical validation of a dual ddPCR assay for detecting carbapenem-resistantFrontiers in microbiology · 2024Article
- Antimicrobial activity of a new class of synthetic retinoid antibiotics and comparator agents against ocular staphylococci.Frontiers in antibiotics · 2023Article
- Article
- Emerging vancomycin-non susceptible coagulase negative Staphylococci associated with skin and soft tissue infections.Annals of clinical microbiology and antimicrobials · 2022Article
- Nocturnal Birds of Prey as Carriers ofAntibiotics (Basel, Switzerland) · 2022Article
- Vancomycin heteroresistance inFuture science OA · 2021Article
- Genomic Insights Into Last-Line Antimicrobial Resistance in Multidrug-ResistantFrontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coagulase-negative staphylococci (CoNS) are a common etiology of serious and recurrent infections in immunocompromised patients. Although most isolates appear susceptible to vancomycin, a single strain might have a subpopulation of resistant bacteria. This phenomenon is termed heteroresistance and may adversely affect the response to treatment. A retrospective cohort study was performed of pediatric patients with leukemia treated at St. Jude Children's Research Hospital who developed CoNS central line-associated bloodstream infection (CLABSI). Available isolates were sequenced and tested for vancomycin heteroresistance by population analysis profiling. Risk factors for heteroresistance and the association of heteroresistance with treatment failure (death or relapse of infection) or poor clinical response to vancomycin therapy (treatment failure or persistent bacteremia after vancomycin initiation) were evaluated. For 65 participants with CoNS CLABSI, 62 initial isolates were evaluable, of which 24 (39%) were vancomycin heteroresistant. All heteroresistant isolates were of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.